Under a contract with Novartis, Harvard Pilgrim will receive a discount from the drug company if its Ernesto treatment for congestive heart failure does not result in a specified drop in patient hospitalizations, according to the article.
Under the other contract, Harvard Pilgrim has agreed to accept a lower rebate from Eli Lilly if its diabetes drug lowers patients’ hemoglobin levels better than drug competitors.
Novartis has already struck outcomes-based contracts for Ernesto with Cigna and Aetna.
More articles on payer issues:
UnitedHealth limits number of in-network insulin pumps, worries consumers
Florida Healthy Kids to end one insurance plan
N.D. insurance commissioner fines Sanford Health Plan over ads
